Soleo Health has been selected by Genentech to dispense two limited distribution drugs, Hemlibra and Ocrevus.
Hemlibra (emicizumab-kxwh), for patients with hemophilia A with factor VIII inhibitors, received approval from the Food and Drug Administration (FDA) in November 2017. Ocrevus (ocrelizumab) is used for patients with relapsing or primary progressive forms of multiple sclerosis and was approved by the FDA in March 2017. Soleo Health has extensive clinical experience in treating patients with these conditions. The company’s trained clinical team has engaged in training and education for the delivery of these two medications.
“The selection of Soleo Health by Genentech is demonstrative of our exceptional clinical experience and service capabilities. We are pleased to be chosen to administer these important life-changing therapies. Being part of manufacturer limited drug distribution networks expands Soleo Health’s clinical service offering for patients, providers and payors, and helps fuel our continued rapid growth. This is a testament to our reputation and commitment to providing outstanding patient care as well as our dedication to improving clinical outcomes,” said Craig Vollmer, executive vice president at Soleo Health.
Contributing to Soleo Health’s participation in limited drug distribution opportunities is its proprietary clinical outcomes program, SoleMetrics, designed to provide customized outcome data for physicians, health systems, accountable care organizations, payors and manufacturers.